Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Pancreas Surgery, Return of Islet Cells

By HospiMedica staff writers
Posted on 04 May 2005
During dual-stage surgery known to have been performed at only two other U.S. More...
centers, doctors returned a patient's own insulin-producing cells to him after surgically removing the pancreas to eliminate constant and severe pain from chronic pancreatitis.

The patient remained anesthetized in the operating room at the University of Alabama (UAB, Birmingham, USA) through the removal of his pancreas and the hours-long wait for the pancreatic islet cells to be processed in a specialized laboratory. The islet cells were then infused into the patient's liver, where they have begun to produce insulin. Few hospitals today have the technologically sophisticated facilities necessary to isolate and purify the pancreatic islet cells.

In the past, pancreatic surgery might have alleviated the pain but would have left the patient with severe, poorly controlled diabetes, since the insulin-producing islets of Langerhans would necessarily be discarded along with the rest of the organ. The new procedure was first performed at the University of Minnesota and the patient still survives. Only a few other cases were attempted, and the results were not uniformly good, so the procedure fell out of favor until recently, when new advances in cadavaric islet cell transplantation made outcomes more favorable.

The current operation was performed by Dr. Selwyn M. Vickers, chief of gastrointestinal surgery at the UAB Pancreaticobiliary Center. The patient's chronic pancreatitis developed four years ago as the result of a congenitally malformed pancreatic duct that closed down following removal of his gallbladder earlier. Three prior operations and several procedures to place stents in the pancreatic duct failed to provide relief. Facing a life of suffering from constant pain, the patient chose the alternative of total removal of the pancreas and the autologous islet cell transplantation.




Related Links:
U. of Alabama

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.